NCT03510884
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
See it on ClinicalTrials.gov ↗306 people
56.9%
43.1%
174 womenmiddle line = equal numbers132 men
- Phase
- PHASE3
- Paid for by
- Sanofi
- Finished
- 2022-08-05
- Health conditions
- Hypercholesterolaemia
- Who could join
- Anyone
- Ages
- 8 Years – 17 Years
- Average age
- mean 13.2 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 81.7% · American Indian / Alaska Native 10.5% · More than one race 3.3% · Black / African American 2% · Asian 1.3% · Native Hawaiian / Pacific Islander 0.7% · Not reported 0.7%
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 17 Years.”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Severe renal impairment (ie, estimated glomerular filtration rate \<30 mL/min/1.73 m\^2).”
- No diabetes
Women with diabetes were turned away.
“Participants with uncontrolled type 1 or type 2 diabetes mellitus.”
Study titles and rules are shown in their original English.